Oncotarget

Research Papers:

High RAC3 expression levels are required for induction and maintaining of cancer cell stemness

Laura C. Panelo, Mileni Soares Machado, María F. Rubio, Felipe Jaworski, Cecilia V. Alvarado, Leonardo A. Paz, Alejandro J. Urtreger, Elba Vazquez and Mónica A. Costas _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:5848-5860. https://doi.org/10.18632/oncotarget.23635

Metrics: PDF 670 views  |   HTML 1580 views  |   ?  


Abstract

Laura C. Panelo1, Mileni Soares Machado1, María F. Rubio1,4,5, Felipe Jaworski4, Cecilia V. Alvarado1, Leonardo A. Paz2, Alejandro J. Urtreger2,3,5, Elba Vazquez4,5 and Mónica A. Costas1,5

1Laboratorio de Biología Moleculary Apoptosis, Instituto de Investigaciones Médicas Alfredo Lanari, IDIM-CONICET, Facultad de Medicina, Universidad de Buenos Aires, C1427ARO Buenos Aires, Argentina

2Laboratorio de Anatomía Patológica, Instituto de Investigaciones Médicas Alfredo Lanari, Facultad de Medicina, Universidad de Buenos Aires, C1427ARO Buenos Aires, Argentina

3Universidad de Buenos Aires, Instituto de Oncología “Angel H Roffo”, Area de Investigación, C1417DTB Buenos Aires, Argentina

4Laboratorio de Inflamación y Cancer, IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, C1428EGA Buenos Aires, Argentina

5Argentine National Research Council (CONICET), C1425FQB Godoy Cruz (CABA), República Argentina

Correspondence to:

Mónica A. Costas, email: mcostasra@hotmail.com

Keywords: RAC3; tumor; cancer stem cell; stem cells; mesenchymal cells

Received: September 12, 2017     Accepted: December 04, 2017     Published: December 22, 2017

ABSTRACT

RAC3 is a transcription coactivator, usually overexpressed in several tumors and required to maintain the pluripotency in normal stem cells.

In this work we studied the association between RAC3 overexpression on cancer cell stemness and the capacity of this protein to induce cancer stem properties in non tumoral cells.

We performed in vitro and in vivo experiments using two strategies: by overexpressing RAC3 in the non tumoral cell line HEK293 and by silencing RAC3 in the human colorectal epithelial cell line HCT116 by transfection. Furthermore, we analysed public repository microarrays data from human colorectal tumors in different developmental stages.

We found that RAC3 overexpression was mainly associated to CD133+ side-population of colon cancer cells and also to early and advanced stages of colon cancer, involving increased expression of mesenchymal and stem markers. In turn, RAC3 silencing induced diminished tumoral properties and cancer stem cells as determined by Hoechst efflux, tumorspheres and clonogenic growth, which correlated with decreased Nanog and OCT4 expression. In non tumoral cells, RAC3 overexpression induced tumoral transformation; mesenchymal phenotype and stem markers expression. Moreover, these transformed cells generated tumors in vivo.

Our results demonstrate that RAC3 is required for maintaining and induction of cancer cell stemness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23635